Literature DB >> 28270967

Normalization of compression-induced hemodynamics in patients responding to neoadjuvant chemotherapy monitored by dynamic tomographic optical breast imaging (DTOBI).

Amir Y Sajjadi1, Steven J Isakoff2, Bin Deng3, Bhawana Singh3, Christy M Wanyo4, Qianqian Fang5, Michelle C Specht6, Lidia Schapira7, Beverly Moy7, Aditya Bardia7, David A Boas3, Stefan A Carp3.   

Abstract

We characterize novel breast cancer imaging biomarkers for monitoring neoadjuvant chemotherapy (NACT) and predicting outcome. Specifically, we recruited 30 patients for a pilot study in which NACT patients were imaged using dynamic tomographic optical breast imaging (DTOBI) to quantify the hemodynamic changes due to partial mammographic compression. DTOBI scans were obtained pre-treatment (referred to as day 0), as well as 7 and 30 days into therapy on female patients undergoing NACT. We present data for the 13 patients who participated in both day 0 and 7 measurements and had evaluable data, of which 7 also returned for day 30 measurements. We acquired optical images over 2 minutes following 4-8 lbs (18-36 N) of compression. The timecourses of tissue-volume averaged total hemoglobin (HbT), as well as hemoglobin oxygen saturation (SO2) in the tumor vs. surrounding tissues were compared. Outcome prediction metrics based on the differential behavior in tumor vs. normal areas for responders (>50% reduction in maximum diameter) vs. non-responders were analyzed for statistical significance. At baseline, all patients exhibit an initial decrease followed by delayed recovery in HbT, and SO2 in the tumor area, in contrast to almost immediate recovery in surrounding tissue. At day 7 and 30, this contrast is maintained in non-responders; however, in responders, the contrast in hemodynamic time-courses between tumor and normal tissue starts decreasing at day 7 and substantially disappears at day 30. At day 30 into NACT, responding tumors demonstrate "normalization" of compression induced hemodynamics vs. surrounding normal tissue whereas non-responding tumors did not. This data suggests that DTOBI imaging biomarkers, which are governed by the interplay between tissue biomechanics and oxygen metabolism, may be suitable for guiding NACT by offering early predictions of treatment outcome.

Entities:  

Keywords:  (170.0170) Medical optics and biotechnology; (170.2655) Functional monitoring and imaging; (170.3880) Medical and biological imaging; (170.3890) Medical optics instrumentation; (170.4580) Optical diagnostics for medicine

Year:  2017        PMID: 28270967      PMCID: PMC5330555          DOI: 10.1364/BOE.8.000555

Source DB:  PubMed          Journal:  Biomed Opt Express        ISSN: 2156-7085            Impact factor:   3.732


  53 in total

1.  Baseline tumor oxygen saturation correlates with a pathologic complete response in breast cancer patients undergoing neoadjuvant chemotherapy.

Authors:  Shigeto Ueda; Darren Roblyer; Albert Cerussi; Amanda Durkin; Anais Leproux; Ylenia Santoro; Shanshan Xu; Thomas D O'Sullivan; David Hsiang; Rita Mehta; John Butler; Bruce J Tromberg
Journal:  Cancer Res       Date:  2012-07-09       Impact factor: 12.701

Review 2.  Neoadjuvant chemotherapy for operable breast cancer.

Authors:  J S D Mieog; J A van der Hage; C J H van de Velde
Journal:  Br J Surg       Date:  2007-10       Impact factor: 6.939

Review 3.  Magnetic resonance spectroscopy of the breast: current status.

Authors:  Patrick J Bolan
Journal:  Magn Reson Imaging Clin N Am       Date:  2013-05-23       Impact factor: 2.266

4.  Optical biomarkers for breast cancer derived from dynamic diffuse optical tomography.

Authors:  Molly L Flexman; Hyun K Kim; Jacqueline E Gunther; Emerson A Lim; Maria C Alvarez; Elise Desperito; Kevin Kalinsky; Dawn L Hershman; Andreas H Hielscher
Journal:  J Biomed Opt       Date:  2013-09       Impact factor: 3.170

5.  Monitoring primary breast cancer throughout chemotherapy using FDG-PET.

Authors:  Garry M McDermott; Andrew Welch; Roger T Staff; Fiona J Gilbert; Lutz Schweiger; Scott I K Semple; Tim A D Smith; Andrew W Hutcheon; Iain D Miller; Ian C Smith; Steven D Heys
Journal:  Breast Cancer Res Treat       Date:  2006-08-09       Impact factor: 4.872

6.  Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors.

Authors:  Valentina Guarneri; Kristine Broglio; Shu-Wan Kau; Massimo Cristofanilli; Aman U Buzdar; Vicente Valero; Thomas Buchholz; Funda Meric; Lavinia Middleton; Gabriel N Hortobagyi; Ana M Gonzalez-Angulo
Journal:  J Clin Oncol       Date:  2006-03-01       Impact factor: 44.544

7.  Digital optical tomography system for dynamic breast imaging.

Authors:  Molly L Flexman; Michael A Khalil; Rabah Al Abdi; Hyun K Kim; Christopher J Fong; Elise Desperito; Dawn L Hershman; Randall L Barbour; Andreas H Hielscher
Journal:  J Biomed Opt       Date:  2011-07       Impact factor: 3.170

8.  Optical imaging of breast cancer oxyhemoglobin flare correlates with neoadjuvant chemotherapy response one day after starting treatment.

Authors:  Darren Roblyer; Shigeto Ueda; Albert Cerussi; Wendy Tanamai; Amanda Durkin; Rita Mehta; David Hsiang; John A Butler; Christine McLaren; Wen-Pin Chen; Bruce Tromberg
Journal:  Proc Natl Acad Sci U S A       Date:  2011-08-18       Impact factor: 11.205

Review 9.  Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy.

Authors:  Rakesh K Jain
Journal:  Science       Date:  2005-01-07       Impact factor: 47.728

10.  Predicting pathologic response to neoadjuvant chemotherapy in breast cancer by using MR imaging and quantitative 1H MR spectroscopy.

Authors:  Hyeon-Man Baek; Jeon-Hor Chen; Ke Nie; Hon J Yu; Shadfar Bahri; Rita S Mehta; Orhan Nalcioglu; Min-Ying Su
Journal:  Radiology       Date:  2009-03-10       Impact factor: 11.105

View more
  7 in total

1.  Longitudinal optical monitoring of blood flow in breast tumors during neoadjuvant chemotherapy.

Authors:  J M Cochran; S H Chung; A Leproux; W B Baker; D R Busch; A M DeMichele; J Tchou; B J Tromberg; A G Yodh
Journal:  Phys Med Biol       Date:  2017-04-12       Impact factor: 3.609

2.  Multimodal breast cancer imaging using coregistered dynamic diffuse optical tomography and digital breast tomosynthesis.

Authors:  Bernhard B Zimmermann; Bin Deng; Bhawana Singh; Mark Martino; Juliette Selb; Qianqian Fang; Amir Y Sajjadi; Jayne Cormier; Richard H Moore; Daniel B Kopans; David A Boas; Mansi A Saksena; Stefan A Carp
Journal:  J Biomed Opt       Date:  2017-04-01       Impact factor: 3.170

3.  Impact of errors in experimental parameters on reconstructed breast images using diffuse optical tomography.

Authors:  Bin Deng; Mats Lundqvist; Qianqian Fang; Stefan A Carp
Journal:  Biomed Opt Express       Date:  2018-02-13       Impact factor: 3.732

4.  Performance assessment of diffuse optical spectroscopic imaging instruments in a 2-year multicenter breast cancer trial

Authors:  Thomas D. O'Sullivan; Albert Cerussi; Amanda Durkin; Brian Hill; Nola Hylton; Arjun G. Yodh; Stefan A. Carp; David Boas; Shudong Jiang; Keith D. Paulsen; Brian Pogue; Darren Roblyer; Wei Yang; Bruce J. Tromberg
Journal:  J Biomed Opt       Date:  2017-08-17       Impact factor: 3.170

5.  Optical Mammography in Patients with Breast Cancer Undergoing Neoadjuvant Chemotherapy: Individual Clinical Response Index.

Authors:  Pamela G Anderson; Sirishma Kalli; Angelo Sassaroli; Nishanth Krishnamurthy; Shital S Makim; Roger A Graham; Sergio Fantini
Journal:  Acad Radiol       Date:  2017-05-19       Impact factor: 3.173

6.  Image processing improvements afford second-generation handheld optoacoustic imaging of breast cancer patients.

Authors:  Jan Kukačka; Stephan Metz; Christoph Dehner; Alexander Muckenhuber; Korbinian Paul-Yuan; Angelos Karlas; Eva Maria Fallenberg; Ernst Rummeny; Dominik Jüstel; Vasilis Ntziachristos
Journal:  Photoacoustics       Date:  2022-03-02

7.  Identifying an early treatment window for predicting breast cancer response to neoadjuvant chemotherapy using immunohistopathology and hemoglobin parameters.

Authors:  Quing Zhu; Susan Tannenbaum; Scott H Kurtzman; Patricia DeFusco; Andrew Ricci; Hamed Vavadi; Feifei Zhou; Chen Xu; Alex Merkulov; Poornima Hegde; Mark Kane; Liqun Wang; Kert Sabbath
Journal:  Breast Cancer Res       Date:  2018-06-14       Impact factor: 6.466

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.